Shire settles dispute with Teva

Published: 3-Dec-2009
Regulatory

Shire, a global biopharmaceutical company, has settled a legal dispute with Teva Pharmaceuticals, the US generic drugs group.


Shire, a global biopharmaceutical company, has settled a legal dispute with Teva Pharmaceuticals, the US generic drugs group.

The disagreement was over Shire's supply to Teva of a generic version of Adderall XR, for attention deficit hyperactivity disorder (ADHD), which Shire claimed had been limited by US Drug Enforcement Administration (DEA) restrictions on amphetamine, which is the product's active ingredient.

Teva, based in Israel, has agreed to drop a lawsuit that claimed Shire had failed to meet its supply contract for Adderall XR.

Shire said after the lawsuit was filed, DEA had granted it with sufficient amphetamines to meet its commitments to Teva.

Teva has now dropped its lawsuit, including its claims for damages.

See more

You may also like

Regulatory

Patent battle for Aloxi in the US

Read more
Helsinn Healthcare and Eisai fall foul of reversed court decision regarding Teva Pharmaceuticals and Aloxi patent for the US market

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Patent battle for Aloxi in the US

Helsinn Healthcare and Eisai fall foul of reversed court decision regarding Teva Pharmaceuticals and Aloxi patent for the US market
Regulatory

Asthma – reslizumab

Acute asthma attacks can require hospitalisation or even prove fatal, but in some sufferers the standard regimen does not give adequate control
Regulatory

Natco Pharma wins US patent case against Teva

Ruling by US Court of Appeals is a major relief to the Indian company
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Regulatory

Teva\'s Cymbalta recall could benefit other players

Market for treatment for depression could still be worth up to US$800m
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Regulatory

Amgen resolves G-CSF patent litigation with Teva

Israeli firm admits Neutroval infringes Amgen patents
Subscribe now